Buscar
Resultados de la búsqueda
- Oncoxin-Viusid/Adenocarcinoma pancreático/Adultos/Fase II
-
... F., Reuter D, Edler L., and Mross K. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor ... et al. Gemcitabine combined with the monoclonal antibody nimotuzumab is an active first-line regimen in KRAS wildtype patients with ...
Ensayos Clínicos - CATALYSIS - 19/07/2023 - 3:58pm
- Nimotuzumab in Non-Small Cell Lung Cancer (NSCLC) of inoperable stage III epidermoid histology, concomitant with Chemo and Radiotherapy (CRT)
-
... Title: Nimotuzumab in NSCLC Scientific title: ... histology NSCLC, treated with concurrent CT-RT plus Nimotuzumab vs concurrent CT-RT. Acronym of ...
Clinical Trials - CIM - 19/07/2023 - 3:22pm
- Nimotuzumab en Cancer de Pulmon de Celulas No pequenas (CPCNP) de histología epidermoides en estadios III inoperables, concomitante con Quimi-RadioTerapia (QRT)
-
... Nimotuzumab en CPCNP Título completo del ... III inoperables, tratados con QT-RT concurrente más Nimotuzumab vs QT-RT concurrente. Siglas ... Nimotuzumab en CPCNP concomitante con QRT ...
Ensayos Clínicos - CIM - 19/07/2023 - 3:21pm
- Safety and efficacy of VAXIRA® in advanced NSCLC patients not progressing after first line chemotherapy. Phase III.
-
... after first line-chemotherapy, treated with VAXIRA® or Nimotuzumab as switch maintenance therapy. ... while patient’s conditions allow it. Control group (Nimotuzumab): 200 mg in 250 ml of saline solution administered intravenously ...
Clinical Trials - CIM - 19/07/2023 - 3:20pm
- Eficacia y seguridad de VAXIRA® en pacientes con CPCNP en estadio avanzado no progresores a primera línea de quimioterapia. Fase III
-
... primera línea de quimioterapia, tratados con VAXIRA® o Nimotuzumab en terapia de mantenimiento de cambio. ... Cáncer de pulmón, Vacuna terapéutica, VAXIRA® , Nimotuzumab Identificador(es) del ...
Ensayos Clínicos - CIM - 19/07/2023 - 3:11pm
- Efficacy and safety of Jusvinza treatment in patients with acute respiratory distress syndrome. Phase II/III
-
... Tocilizumab), anti-IL-1 monoclonal antibody (eg Anakinra), Nimotuzumab or Itolizumab 6) Patient currently participating in another ...
Clinical Trials - CIGB - 02/05/2023 - 1:29pm
- Eficacia y seguridad del tratamiento con Jusvinza en pacientes con síndrome de distrés respiratorio agudo. Fase II/III
-
... anticuerpo monoclonal anti-IL-1 (ej. Anakinra), Nimotuzumab o Itolizumab 6) Paciente participante actual en otro ensayo ...
Ensayos Clínicos - CIGB - 24/04/2023 - 3:58pm
- CIMAvax-EGF in Bladder cancer
-
... with the therapeutic vaccine CIMAvax®EGF and / or Nimotuzumab (Therapeutic monoclonal antibody hR3), or any other product under ...
Clinical Trials - CIM - 24/03/2023 - 7:33am
- CIMAvax-EGF en Cáncer de Vejiga
-
... tratamiento con la vacuna terapéutica CIMAvax®EGF y/o Nimotuzumab (Anticuerpo monoclonal terapéutico hR3), o cualquier otro producto ...
Ensayos Clínicos - CIM - 24/03/2023 - 7:33am
- Nimotuzumab in the treatment of patients with acute respiratory difficulty syndrome (ARDS)
-
... and preliminary effect of the monoclonal antibody Nimotuzumab in the treatment of patients with acute respiratory distress ... Group I (Experimental) MAb Nimotuzumab, 200 mg the first dose followed by 100 mg doses separated by 72 ...
Clinical Trials - CIM - 03/03/2023 - 4:06pm